Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells
Ben‐Yuan Jiang(Guangdong Academy of Medical Sciences), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Chong‐Rui Xu(Guangdong Academy of Medical Sciences), Bin-Chao Wang(Guangdong Academy of Medical Sciences), Biao Huang(Guangdong Academy of Medical Sciences), Shuyu Wu(Xiamen University), Hai‐Yan Tu(Jiangnan University), Xue‐Ning Yang(Guangdong Academy of Medical Sciences), Xu‐Chao Zhang(Guangdong Academy of Medical Sciences), Cun-Yi Gao(Beike Biotechnology (China)), Wen‐Zhao Zhong(Guangdong Academy of Medical Sciences), Qing Zhou(Jiangnan University), Zhen Wang(Ministry of Education), Zhihong Chen(Shenzhen Center for Disease Control and Prevention), Xian Zhang(SUNY Geneseo), Jin‐Ji Yang(Guangdong General Hospital), Yan‐Hui Liu(Hainan University), Hua‐Jun Chen(Fujian Medical University), Jian Su(Fujian Normal University), Yang Shao(Sanya University), Wei‐Bang Guo(Guangdong General Hospital), Yang-Si Li(Guangdong Academy of Medical Sciences)
Cited by 136
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k